A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency.

NCT00294619 Phase 3 COMPLETED

The purpose of this study is to evaluate efficacy and safety profile of a new weekly administered growth hormone preparation compared with placebo in adults with growth hormone deficiency.

Details

Lead sponsor	LG Life Sciences
Phase	Phase 3
Status	COMPLETED
Enrolment	147
Start date	2006-04
Completion	2008-03

Conditions

• Pituitary Disorders
• Adult Growth Hormone Deficiency

Interventions

• growth hormone

Primary outcomes

• Changes in Fat Mass at the end of 26-week treatment from baseline — 26 weeks

Countries

United States